Literature DB >> 34002028

Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Michele Baccarani1, Robert Peter Gale2.   

Abstract

Entities:  

Year:  2021        PMID: 34002028     DOI: 10.1038/s41375-021-01272-8

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  54 in total

1.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Authors:  Susanne Saussele; Johan Richter; Joelle Guilhot; Franz X Gruber; Henrik Hjorth-Hansen; Antonio Almeida; Jeroen J W M Janssen; Jiri Mayer; Perttu Koskenvesa; Panayiotis Panayiotidis; Ulla Olsson-Strömberg; Joaquin Martinez-Lopez; Philippe Rousselot; Hanne Vestergaard; Hans Ehrencrona; Veli Kairisto; Katerina Machová Poláková; Martin C Müller; Satu Mustjoki; Marc G Berger; Alice Fabarius; Wolf-Karsten Hofmann; Andreas Hochhaus; Markus Pfirrmann; Francois-Xavier Mahon
Journal:  Lancet Oncol       Date:  2018-05-04       Impact factor: 41.316

2.  Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.

Authors:  Stéphanie Dulucq; Cyril Astrugue; Gabriel Etienne; François-Xavier Mahon; Antoine Benard
Journal:  Br J Haematol       Date:  2020-02-19       Impact factor: 6.998

3.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 4.  Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.

Authors:  Leonardo Campiotti; Matteo Basilio Suter; Luigina Guasti; Rocco Piazza; Carlo Gambacorti-Passerini; Anna Maria Grandi; Alessandro Squizzato
Journal:  Eur J Cancer       Date:  2017-03-30       Impact factor: 9.162

5.  The impact of health care settings on survival time of patients with chronic myeloid leukemia.

Authors:  Michael Lauseker; Joerg Hasford; Markus Pfirrmann; Rüdiger Hehlmann
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

6.  Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Authors:  Michele Baccarani; Elisabetta Abruzzese; Vincenzo Accurso; Francesco Albano; Mario Annunziata; Sara Barulli; Germana Beltrami; Micaela Bergamaschi; Gianni Binotto; Monica Bocchia; Giovanni Caocci; Isabella Capodanno; Francesco Cavazzini; Michele Cedrone; Marco Cerrano; Monica Crugnola; Mariella D'Adda; Chiara Elena; Carmen Fava; Paola Fazi; Claudio Fozza; Sara Galimberti; Valentina Giai; Antonella Gozzini; Gabriele Gugliotta; Alessandra Iurlo; Gaetano La Barba; Luciano Levato; Alessandro Lucchesi; Luigia Luciano; Francesca Lunghi; Monia Lunghi; Michele Malagola; Roberto Marasca; Bruno Martino; Angela Melpignano; Maria Cristina Miggiano; Enrico Montefusco; Caterina Musolino; Fausto Palmieri; Patrizia Pregno; Davide Rapezzi; Giovanna Rege-Cambrin; Serena Rupoli; Marzia Salvucci; Rosaria Sancetta; Simona Sica; Raffaele Spadano; Fabio Stagno; Mario Tiribelli; Simona Tomassetti; Elena Trabacchi; Massimiliano Bonifacio; Massimo Breccia; Fausto Castagnetti; Fabrizio Pane; Domenico Russo; Giuseppe Saglio; Simona Soverini; Paolo Vigneri; Gianantonio Rosti
Journal:  Blood Adv       Date:  2019-12-23

Review 7.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

8.  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Authors:  R Hehlmann; M Lauseker; S Saußele; M Pfirrmann; S Krause; H J Kolb; A Neubauer; D K Hossfeld; C Nerl; A Gratwohl; G M Baerlocher; D Heim; T H Brümmendorf; A Fabarius; C Haferlach; B Schlegelberger; M C Müller; S Jeromin; U Proetel; K Kohlbrenner; A Voskanyan; S Rinaldetti; W Seifarth; B Spieß; L Balleisen; M C Goebeler; M Hänel; A Ho; J Dengler; C Falge; L Kanz; S Kremers; A Burchert; M Kneba; F Stegelmann; C A Köhne; H W Lindemann; C F Waller; M Pfreundschuh; K Spiekermann; W E Berdel; L Müller; M Edinger; J Mayer; D W Beelen; M Bentz; H Link; B Hertenstein; R Fuchs; M Wernli; F Schlegel; R Schlag; M de Wit; L Trümper; H Hebart; M Hahn; J Thomalla; C Scheid; P Schafhausen; W Verbeek; M J Eckart; W Gassmann; A Pezzutto; M Schenk; P Brossart; T Geer; S Bildat; E Schäfer; A Hochhaus; J Hasford
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

Review 9.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

Review 10.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Authors:  A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528

View more
  6 in total

1.  Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.

Authors:  Nicoletta Vitale; Francesca Orso; Mohammad Houshmand; Alessandro Cignetti; Ivan Molineris; Valentina Gaidano; Stefano Sainas; Marta Giorgis; Donatella Boschi; Carmen Fava; Alice Passoni; Marta Gai; Massimo Geuna; Federica Sora; Alessandra Iurlo; Elisabetta Abruzzese; Massimo Breccia; Olga Mulas; Giovanni Caocci; Fausto Castagnetti; Daniela Taverna; Salvatore Oliviero; Fabrizio Pane; Marco Lucio Lolli; Paola Circosta; Giuseppe Saglio
Journal:  Cell Death Dis       Date:  2022-06-30       Impact factor: 9.685

2.  Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells.

Authors:  Stella Pearson; Anthony D Whetton; Andrew Pierce
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

3.  [Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].

Authors:  Y L Chen; J Zou; Y L Zhang; W M Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-05-14

4.  Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients' CD34+/CD38- Leukemia Stem Cells.

Authors:  Iga Stukan; Marek Gryzik; Grażyna Hoser; Andrew Want; Wioleta Grabowska-Pyrzewicz; Mikolaj Zdioruk; Mariola Napiórkowska; Marcin Cieślak; Karolina Królewska-Golińska; Barbara Nawrot; Grzegorz Basak; Urszula Wojda
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

5.  Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.

Authors:  Susanna Vuorenoja; Kim Vettenranta; Olli Lohi
Journal:  Cancer Rep (Hoboken)       Date:  2022-07-07

Review 6.  Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.

Authors:  Michele Baccarani; Francesca Bonifazi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Wael Saber; Noel Estrada-Merly; Gianantonio Rosti; Robert Peter Gale
Journal:  Leukemia       Date:  2022-03-25       Impact factor: 12.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.